Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?

NCT ID NCT07758816

Recruiting now Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study follows 30 people with Gaucher disease who are receiving standard medical care to better understand how the condition affects the lungs, bones, and nervous system over time. Researchers will track changes in breathing, bone density, and neurological signs, along with blood markers, to see how the disease progresses despite treatment. The goal is to uncover patterns that could guide smarter, combination therapies for the toughest symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: This research could reveal how Gaucher disease progresses despite current treatments, pointing toward better monitoring and combination therapies for stubborn bone, lung, and brain symptoms.
What could go wrong: This is an observational study, not a treatment test, so it won't directly show whether a new drug works. Findings may take years to influence care and might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Gaucher disease Gaucher disease type II Gaucher disease type III Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GAUCHER DISEASE

Contacts and locations

Locations

Yale New Haven Health System
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.